Phase I study of amonafide + cytosine arabinoside (AraC) in patients with poor risk acute myeloid leukemia (AML)

Autor:	R. Dubon, M. Drouin, C. K. Grieshaber, Jonathan E. Kolitz, M. A. Boss, M. Champagne, Steven L. Allen, Daniel R. Budman, Ante Sven Lundberg, S. Devost
Rok vydání:	2005
Předmět:	Response rate (survey) Cancer Research Poor risk business.industry Myeloid leukemia Amonafide medicine.disease Prostate cancer chemistry.chemical_compound Breast cancer Oncology chemistry medicine Cancer research In patient business Cytosine
Zdroj:	Journal of Clinical Oncology. 23:6602-6602
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.6602
Popis:	6602 Background: Amonafide (Am) is an ATP independent topoisomerase 2 inhibitor that in prior clinical studies demonstrated activity in breast cancer (18–25% response rate (RR)) and prostate cancer...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5baee6deec7a79f21a28ff9cf26d7a83 https://doi.org/10.1200/jco.2005.23.16_suppl.6602 Zobrazit plný text záznamu